Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and $14 price target on Progenics Pharmaceuticals (NASDAQ: PGNX) after the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Oral Relistor Approval the First of Many Progenics Pharmaceuticals (PGNX) Drivers - Needham & CompanyJuly 20, 2016 9:16 AM Progenics Pharma (PGNX) Surges Over 20% as FDA Approval Oral RELISTORJuly 20, 2016 8:10 AM BTIG Positive on Progenics Pharma (PGNX) Following FDA Approval of RELISTOR as OIC Treatment (VRX)July 20, 2016 7:57 AM Progenics (PGNX) volatility elevated into FDA approval of constipation treatment July 20, 2016 5:43 AM Valeant Pharma (VRX), Progenics Pharmaceuticals (PGNX) Granted FDA Approval for RELISTORJuly 19, 2016 6:06 PM Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer PainJuly 19, 2016 6:04 PM